Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer

Figure 3 Decrease of angiopoietin-2 in plasma in function of time. The percentage of the decrease of angiopoietin-2 (Ang-2) level in plasma as respect the baseline level (before the beginning of therapy) is reported in function of timing after therapy, before the 2^nd and the 5^th cycle.